The production license follows the issuance of the New Animal Drug Certificate and the Certificate of Good Manufacturing Practices for Animal Drugs (GMP Certificate) by the MOA.
Sinovac chairman, president and CEO Weidong Yin said receiving the production license for their animal rabies vaccines is a significant milestone as it represents the final step in the regulatory process before they launch this vaccine in China.
"We have established a dedicated sales force and are teaming up with distributors to make this first China developed and manufactured inactivated animal rabies vaccine available to pet owners through the animal CDC’s and veterinary hospitals," Yin said.